<DOC>
	<DOC>NCT02568397</DOC>
	<brief_summary>The purpose of this study is to learn about the effect of AZD3293 on how the body absorbs and processes dabigatran etexilate and how dabigatran etexilate affects AZD3293 when they are taken together. This study will last about 28 days and participants will be asked to take an AZD3293 tablet daily for 19 days and a dabigatran etexilate tablet on 3 occasions. Screening is required within 30 days prior to the start of the study.</brief_summary>
	<brief_title>A Drug-drug Interaction Study of AZD3293 (LY3314814) in Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Overtly healthy males and females Eye abnormalities or disease History of vitiligo or any skin color disorder Have a history psychiatric or brain disease including seizures Have smoked within the last 3 months Are unwilling to avoid food and drinks containing grapefruit or Seville oranges for the duration of the study Have known allergies to dabigatran etexilate and related compounds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>